Tocagen Inc (NASDAQ:TOCA) reached a new 52-week low during trading on Friday . The company traded as low as $8.14 and last traded at $8.45, with a volume of 475 shares trading hands. The stock had previously closed at $8.20.

A number of equities research analysts have recently commented on TOCA shares. Zacks Investment Research cut Tocagen from a “hold” rating to a “sell” rating in a research report on Thursday. B. Riley initiated coverage on Tocagen in a research report on Wednesday, May 16th. They set a “buy” rating and a $15.00 target price on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Tocagen in a research note on Wednesday, June 27th. They issued a “buy” rating and a $20.00 price target on the stock. HC Wainwright initiated coverage on shares of Tocagen in a research note on Monday, June 11th. They issued a “buy” rating and a $14.50 price target on the stock. Finally, ValuEngine raised shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Monday, July 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $15.13.

The company has a market cap of $180.76 million, a price-to-earnings ratio of -3.05 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.56 and a current ratio of 4.56.

Tocagen (NASDAQ:TOCA) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.25). The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $2.01 million. Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 70.79%. analysts predict that Tocagen Inc will post -2.07 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new position in Tocagen in the 4th quarter valued at about $122,000. Rhumbline Advisers purchased a new position in Tocagen in the 1st quarter valued at about $178,000. Raymond James & Associates purchased a new position in Tocagen in the 2nd quarter valued at about $142,000. First Republic Investment Management Inc. purchased a new position in Tocagen in the 2nd quarter valued at about $170,000. Finally, Teachers Advisors LLC lifted its stake in Tocagen by 40.7% in the 4th quarter. Teachers Advisors LLC now owns 21,163 shares of the company’s stock valued at $217,000 after buying an additional 6,120 shares in the last quarter. 32.11% of the stock is currently owned by hedge funds and other institutional investors.

About Tocagen (NASDAQ:TOCA)

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Recommended Story: Marijuana Stocks Investing Considerations

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.